Historic agreements show power of innovative public-private partnership
View infographic to see how GAVI’s support for HPV vaccines will help redress the inequity, delivering vaccines to countries with the highest burden. Download as PDF.
Cape Town /
Geneva, 9 May 2013 – A new record low
price for human papillomavirus (HPV) vaccines will help ensure millions of
girls in developing countries can be protected against cervical cancer.
Thanks to the GAVI Alliance, the poorest countries will now have access
to a sustainable supply of HPV vaccines for as low as US$ 4.50 per dose. The same vaccines can cost more than $100 in developed countries and the
previous lowest public sector price was $13 per dose.
HPV vaccines are primarily available as part of routine immunisation to
girls in relatively wealthy countries. And yet of the 275,000 women in the
world who die of cervical cancer every year, more than 85% are in low-income
countries, where the incidence of HPV infection is higher and few women have
access to screening and treatment.
A vast health gap currently exists between girls in rich and poor countries. With GAVI’s programmes we can begin to bridge that gap
Dr Seth Berkley, CEO of the GAVI Alliance
“A vast health gap currently exists between girls in rich and poor
countries. With GAVI’s programmes we can begin to bridge that gap so that all
girls can be protected against cervical cancer no matter where they are born,” said
Dr Seth Berkley, CEO of the GAVI Alliance. “By 2020 we hope to reach more than
30 million girls in more than 40 countries. This is a transformational moment
for the health of women and girls across the world. We thank the manufacturers
for working with us to help make this happen.”
Today’s announcement was made possible through GAVI’s innovative
public-private partnership model, which was launched at the World Economic
Forum in 2000 to meet the challenges of getting vaccines out to some of the
least wealthy developing countries. GAVI’s recent market shaping activities
have also achieved significant reductions for pentavalent and rotavirus
vaccines while simultaneously helping to create healthier and more secure
markets for vaccines.
First eight countries
GAVI will begin support for HPV vaccines in
Kenya as early as this month followed by Ghana, Lao PDR, Madagascar, Malawi,
Niger, Sierra Leone and the United Republic of Tanzania.
As these demonstration
programmes reach pre-adolescents – a group not currently targeted for
immunisation -- they will give each country the opportunity to demonstrate their
ability to put in place the systems needed to run national programmes. GAVI
will also support HPV vaccines for nationwide use in Rwanda next year. The
immunisation of girls aged nine to 13 also provides an opportunity to reach
adolescents with education programmes on nutrition, sexual health and HIV
Halving the time lag
As well as bringing down dramatically the price of the HPV vaccines,
GAVI has also helped to halve the time lag that can exist in getting new
vaccines out to poor countries, down to just six years.
Since GAVI began accepting applications for HPV vaccines support in 2012
it has received unprecedented demand, with 15 countries applying last year and a
further 15 to 20 expected this year.
Developing countries bear an increasing burden of cervical cancer and it is only right that our girls should have the same protection as girls in other countries
Dr Richard Sezibera, Secretary General of the East African Community
”Developing countries bear an increasing burden of cervical cancer and
it is only right that our girls should have the same protection as girls in
other countries,” said Dr Richard Sezibera, Secretary General of the East
African Community, GAVI Board member and former Health Minister of Rwanda. “In
Africa, where facilities to diagnose and treat cervical cancer are few and far
between, HPV vaccines will mean the difference between life and death for so
many women in the prime of their lives.”
“Vaccinating girls against HPV can be a key component of a national
strategy to prevent and control cervical cancer across a woman’s life course,”
said Dr Flavia Bustreo, Assistant Director General at the World Health
Organization. “This new price reduction is a great step forward for women and
girls: we look forward to working with countries to incorporate the HPV vaccine
into their national immunisation programmes.”
Shaping the market
UNICEF as procurement partner for the GAVI
Alliance have run a public tender process and will now purchase HPV vaccines
from Merck & Co. at US$ 4.50 per dose and from GlaxoSmithKline at US$ 4.60 per
dose for the award period, 2013-2017. Additionally, Merck has agreed to extend significantly
lower prices to GAVI if total volumes increase in the future.
The market shaping efforts of the GAVI Alliance work to address market
failures for vaccines by aggregating volume, increasing certainty of demand, stimulating
competition where possible and ensuring that a sufficient quantity of
appropriate, quality vaccines is available through a diverse manufacturer base
at affordable and sustainable prices.
With this price agreement now in place the GAVI Alliance Secretariat will
work with partners to implement the GAVI HPV Vaccine Programme. Among
stakeholders involved are the World Health Organization, PATH, UNICEF, UNFPA, National
Cancer Institute, World Bank, Union for International Cancer Control, Pink
Ribbon Red Ribbon, UNAIDS, International Agency for Research on Cancer, and the
US Centers for Disease Control.
GAVI is funded by governments [Australia, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Luxembourg, Netherlands, Norway, Republic of Korea, Russia, South Africa, Spain, Sweden, United Kingdom, United States], the European Commission, the Bill & Melinda Gates Foundation, as well as private and corporate partners [Absolute Return for Kids, Anglo American plc., The Children’s Investment Fund Foundation, Comic Relief, Dutch Postcode Lottery, His Highness Sheikh Bin Zayed Al Nahyan, JP Morgan, “la Caixa” Foundation, LDS Charities and Vodafone].
Click to view the full donor list.